Literature DB >> 32133618

Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.

P Gisondi1, C Virga1, S Piaserico2, A Meneguzzo2, G Odorici3, A Conti3, G Girolomoni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32133618     DOI： 10.1111/bjd.19013

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab.

Authors:  Sarah Fischer; Sarah Cohnen; Entcho Klenske; Heike Schmitt; Francesco Vitali; Simon Hirschmann; Andreas Ramming; Sebastian Zundler; Timo Rath; Sabine Krebs; Frank Dörje; Wolfgang Uter; Daniel Nagore; Sebastian Meyer; Markus F Neurath; Raja Atreya
Journal:  Therap Adv Gastroenterol       Date:  2021-01-14       Impact factor: 4.409

2.  Switching Among Biosimilars: A Review of Clinical Evidence.

Authors:  Eleonora Allocati; Brian Godman; Marco Gobbi; Silvio Garattini; Rita Banzi
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

3.  Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program "Treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.

Authors:  Witold Owczarek; Irena Walecka; Agnieszka Nowakowska; Piotr Ciechanowicz; Adam Reich; Aleksandra Lesiak; Ewa Borkowska; Andrzej Śliwczyñski; Joanna Narbutt
Journal:  Postepy Dermatol Alergol       Date:  2021-08-16       Impact factor: 1.664

4.  Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.

Authors:  Hillel P Cohen; Sohaib Hachaichi; Wolfram Bodenmueller; Tore K Kvien; Silvio Danese; Andrew Blauvelt
Journal:  BioDrugs       Date:  2022-07-26       Impact factor: 7.744

5.  Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.

Authors:  Lauranne A A P Derikx; Heather W Dolby; Nikolas Plevris; Laura Lucaciu; Caitlin S Rees; Mathew Lyons; Spyros I Siakavellas; Nathan Constantine-Cooke; Philip Jenkinson; Shanna Su; Claire O'Hare; Laura Kirckpatrick; Lynne M Merchant; Colin Noble; Ian D Arnott; Gareth-Rhys Jones; Charlie W Lees
Journal:  J Crohns Colitis       Date:  2021-12-18       Impact factor: 9.071
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.